본문 바로가기
HOME> 논문 > 논문 검색상세

논문 상세정보

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences v.1072, 2018년, pp.244 - 251   SCI SCIE
본 등재정보는 저널의 등재정보를 참고하여 보여주는 베타서비스로 정확한 논문의 등재여부는 등재기관에 확인하시기 바랍니다.

Metabolite identification and pharmacokinetic profiling of PP242, an ATP-competitive inhibitor of mTOR using ultra high-performance liquid chromatography and mass spectrometry

Rashid, Md. Mamunur (Molecular Recognition Research Center, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea ) ; Lee, Hyunbeom (Molecular Recognition Research Center, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea ) ; Jung, Byung Hwa (Molecular Recognition Research Center, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea ) ;
  • 초록  

    Abstract PP242 is a second generation novel selective ATP-competitive inhibitor of mTOR that displayed promising anti-cancer activity over several cancer types by inhibiting both the complexes of mTOR (mTORC1 and mTORC2). The purpose of this study is to identify the possible metabolites and to evaluate the pharmacokinetic profile of PP242 after a single oral administration to Sprague-Dawley (SD) rats. Two metabolites, including one phase I and one phase II, were identified by in vitro and in vivo studies using rat liver microsomes (RLMs) as well as rat plasma, urine and feces, respectively, through ultra high-performance liquid chromatography-linear ion trap quadrupole-orbitrap-mass spectrometry (UHPLC-LTQ-Orbitrap-MS). The major biotransformation pathways of PP242 were hydroxylation and glucuronide conjugation. Additionally, a simple and rapid quantification method was developed and validated. The method recovery was within 79.7–84.6%, whereas the matrix effect was 78.1-96.0% in all three quality control (QC) concentrations (low, medium and high) including the LLOQ. Other parameters showed acceptable results according to the US food and drug administration (FDA) guidelines for bioanalytical method validation. Afterwards, pharmacokinetic parameters were evaluated in rat plasma by successfully applying the validated method using liquid chromatography-tandem mass spectrometry (LC–MS/MS). After a single oral administration at a dose of 5mg/kg, the maximum plasma concentration (C max ) of PP242 was 0.17±0.08μg/mL, while the elimination was moderately fast (T 1/2 : 172.18±45.54min). All of the obtained information on the metabolite identification and pharmacokinetic parameter elucidation could facilitate the further development of PP242. Highlights Metabolite identification and pharmacokinetic analysis of PP242 were performed in SD rats. A phase I and a phase II metabolites were identified by the in vitro and in vivo studies. Hydroxylation and glucuronide conjugation were the major pathways for the PP242 metabolism in rats. The C max was 0.17±0.08μg/mL, and T 1/2 was 172.18±45.54min.


  • 주제어

    PP242 .   mTOR inhibitor .   UHPLC-LTQ-Orbitrap-MS .   Pharmacokinetic profiling .   LC–MS/MS.  

 활용도 분석

  • 상세보기

    amChart 영역
  • 원문보기

    amChart 영역

원문보기

무료다운로드
  • 원문이 없습니다.

유료 다운로드의 경우 해당 사이트의 정책에 따라 신규 회원가입, 로그인, 유료 구매 등이 필요할 수 있습니다. 해당 사이트에서 발생하는 귀하의 모든 정보활동은 NDSL의 서비스 정책과 무관합니다.

원문복사신청을 하시면, 일부 해외 인쇄학술지의 경우 외국학술지지원센터(FRIC)에서
무료 원문복사 서비스를 제공합니다.

NDSL에서는 해당 원문을 복사서비스하고 있습니다. 위의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.

이 논문과 함께 출판된 논문 + 더보기